SCYNEXIS, Inc.

SCYX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Revenue $20.6M $3.7M $140.1M $5.1M $13.2M $0 $121.0K $257.0K
Cost of Revenue — — — — — — — —
Gross Profit — — — — — — — —
Gross Margin — — — — — — — —
Operating Expenses
Research & Development $22.3M $26.4M $30.9M $27.3M $23.8M $36.5M $38.4M $21.6M
SG&A Expense $14.4M $14.5M $20.9M $63.0M $49.9M $14.6M $10.6M $8.7M
Operating Income $-16.1M $-37.1M $72.7M $-85.8M $-60.8M $-51.1M $-48.9M $-30.0M
Operating Margin -78.0% -990.8% 51.9% -1,684.5% -462.2% — -40,430.6% -11,666.5%
Interest Expense — — $3.1M $5.2M $2.7M $1.2M $986.0K $1.6M
Pretax Income $-8.6M $-21.1M $67.2M $-67.5M $-36.0M $-58.3M $-53.7M $-19.2M
Income Tax Expense $0 $151.0K $138.0K $-4.7M $-3.1M $-3.1M $0 $-6.7M
Net Income $-8.6M $-21.3M $67.0M $-62.8M $-32.9M $-55.2M $-53.7M $-12.5M
Net Margin -41.8% -568.3% 47.8% -1,233.7% -249.7% — -44,388.4% -4,851.4%
EPS (Basic) $-0.17 $-0.44 $1.40 $-1.47 $-1.25 — $-0.96 $-0.28
EPS (Diluted) $-0.17 $-0.44 $1.39 $-1.47 $-1.25 — — —
Shares Outstanding (Basic) 49.9M 48.5M 47.9M 42.6M 26.4M 19.7M 9.7M 48.0M
Shares Outstanding (Diluted) 49.9M 48.5M 48.4M 42.6M 26.4M 19.7M 9.7M 48.0M
Dividends Per Share — — — — — — — —
← Newer Page 1 of 2 Older →